MedTrace Logo

Use of Bivalirudin for Anticoagulation in Patients With Extracorporeal Membrane Oxygenation

NCT06275555 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 154

Last updated 2026-04-06

No results posted yet for this study

Summary

The purpose of this study was to evaluate the efficacy and safety of bivalirudin in anticoagulation therapy in patients with extracorporeal membrane oxygenation (ECMO) compared with unfractionated heparin.

Conditions

  • Extracorporeal Membrane Oxygenation Complication

Interventions

DRUG

bivalirudin

bivalirudin as an anticoagulant

DRUG

unfractionated heparin

unfractionated heparin as an anticoagulant

Sponsors & Collaborators

  • Xiaotong Hou

    lead OTHER

Principal Investigators

  • Liangshan Wang, MD · Beijing Anzhen Hospital

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-03
Primary Completion
2026-12-31
Completion
2027-03-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06275555 on ClinicalTrials.gov